harvoni
Gilead to release generic versions of hep C meds over a decade before patent expiry
September 28, 2018Medical Communications, Sales and Marketing Epclusa, Gilead, generics, harvoni, hepatitis C, pharma
Gilead has announced its intention to undercut itself by releasing generic versions of its blockbuster drugs for the treatment of …
US court upholds verdict voiding MSD’s claim to $200m from Gilead in patent dispute
April 26, 2018Sales and Marketing Gilead, MSD, Merck, harvoni, hepatitis C, pharma, sovaldi
MSD has taken a legal hit after a US appeals court upheld a ruling that the pharma giant had illicitly …
Long-running, $2.5bn lawsuit swings in Gilead’s favour
February 19, 2018Sales and Marketing Gilead, MSD, biotech, drugs, harvoni, pharma, pharmaceutical, sovaldi
The fate of pharma company’s profits and losses largely rests on product approvals and the sales team behind them but, …
FDA approves first two antiviral hep C drugs for paediatric patients
April 10, 2017Sales and Marketing FDA, harvoni, hepatitis C, sovaldi
The FDA has given the go-ahead for two hepatitis C treatments for use in young and adolescent patients: Sovaldi (sofosbuvir) …
Gilead presents data highlighting progress and efficacy in liver and hepatitis C therapies
April 20, 2016Research and Development, Sales and Marketing Gilead, harvoni, hepatitis, liver, sofosbuvir
Gilead (NASDAQ: GILD) has presented a broad range of results on its current and potential therapeutics at the International Liver …
Gilead must pay MSD $200m in hep C drug patent case
March 29, 2016Manufacturing and Production, Sales and Marketing Gilead Sciences, MSD, Solvadi, harvoni
A Californian federal jury has ordered Gilead Sciences to pay MSD and Ionis $200 million for infringing on patents relating …
FDA approves Gilead’s Harvoni in two new indications
February 18, 2016Research and Development Gilead Sciences, MSD, harvoni, hepatitis C
The hepatitis C treatment battle had its latest development yesterday, with the FDA awarding Gilead Science’s market-leading drug Harvoni (ledipasvir/sofosbuvir) …
MSD’s Zepatier approval could spell end of Gilead’s Hep C dominance, says analyst
February 10, 2016Sales and Marketing AbbVie, Drug pricing, Gilead Sciences, MSD, Solvadi, Viekira Pak, harvoni, hepatitis C
The introduction of MSDs’ recently FDA-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market …
FDA expands Gilead’s Harvoni indications for Hep C
November 13, 2015Sales and Marketing Gilead, Gilead Sciences, harvoni, ledipasvir-sofosbuvir
Gilead’s Harvoni has been approved by the FDA for expanded use in patients with genotypes 4, 5 and 6 chronic …
NICE to recommend three new treatments for hep C
October 16, 2015Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C
NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …
NICE restricts access to new hepatitis C treatments
July 29, 2015Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, daklinza, harvoni, hepatits C
NICE has recommended three new treatment options for hepatitis C in draft guidance – but has been criticised for excluding …
NICE recommends Harvoni for hepatitis C
March 3, 2015Sales and Marketing Gilead, NICE, harvoni, hepatitis C, ledipasvir-sofosbuvir
NICE has signalled a provisional OK for Gilead’s Harvoni to be used as a treatment for hepatitis C by the …
Gilead sales soar on back of hepatitis drugs
February 4, 2015Sales and Marketing Atripla, Gilead, efavirenz, emtricitabine, harvoni, lepidasvir, q4, sofosbuvir, sovaldi, tenofovi
The new blockbuster hepatitis C treatments Sovaldi and Harvoni more than doubled Gilead’s sales in the last quarter of 2014 …
AbbVie Hep C combo pill ready for Europe
January 16, 2015Medical Communications AbbVie, Exviera, FDA, HIV, Viekira Pak, Viekirax, harvoni, hep C, sovaldi
The European Commission has approved AbbVie’s Viekirax and Exviera for the treatment of chronic hepatitis C (HCV). Viekirax (ombitasvir/paritaprevir/ritonavir) and …
Pharma industry set for bumper 2015
January 5, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2015, FDA, bumper, harvoni, opdivo, pharma, sovaldi
Industry analysts predict 2015 will be another year of growth for the pharma, after approvals of new drugs soared to …
Latest content
Five Facts about cardiovascular disease
